Advice

in the absence of a submission from the holder of the marketing authorisation:

midostaurin (Rydapt®) is not recommended for use within NHSScotland.

Indication under review: as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell leukaemia.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download full details135KB (PDF)

Download

Medicine details

Medicine name:
midostaurin (Rydapt)
SMC ID:
SMC2100
Indication:
as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell leukaemia.
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
09 July 2018